Haematologica

Aims & Scope

Haematologica publishes articles in the broad field of hematology, reporting on novel findings in basic, clinical and translational research.

The scope of the journal is to report novel research results that have an important impact on our understanding of normal hematology or the development of hematological diseases, or are likely to bring important changes to the diagnosis or treatment of hematological diseases.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science
• Medline
• PubMed
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Apc url
• License

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 3,000.00 EUR. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients

  Citation: 613

  Authors: P., F., A., V., E., R., M., D., P., A.

• Iron metabolism and iron disorders revisited in the hepcidin era

  Citation: 522

  Authors: Clara, Antonella, Laura

• ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

  Citation: 518

  Authors: Frederic, Samir, Livio, Georgios, Andreas H., Anna, Cornelia, Thierry, Claudio, Raoul

• European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia

  Citation: 478

  Authors: D., C., C., D. M., M., C., I. C., W. V., G., O., D., M.

• Pediatric acute lymphoblastic leukemia

  Citation: 429

  Authors: Hiroto, Charles G.

• Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

  Citation: 413

  Authors: C., E., U.-H., O., M., M., C., I., S. Y.

• Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

  Citation: 402

  Authors: A. C., A., M., L., R. A., H., K., G., J., D., L., M., G., R., A. K., P., C., M. P., M., M., G., A., M., C., M., R. M., E., N., R. G., J. F., P., H. E.

• Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

  Citation: 384

  Authors: Anthony R., Chadhi, Meghan C., Nicole, Danielle M., Brian, Christina, Alan, Bruce D., Clive, Jeffrey, Pavel, Andre, David, Krista, Kaitlin H., Colleen, Daniel, Allison, Sunita D., Spencer H., Stephen J., Colleen, Jakub, Paul, Chaitra S.

• Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor- 1

  Citation: 370

  Authors: M. J., M., A., T. L., M.

• Survival for older patients with acute myeloid leukemia: a population-based study

  Citation: 352

  Authors: B., D. J.